These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25609451)

  • 1. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
    Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
    Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
    Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
    Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).
    Wang X; Wang Y; Qiu M; Li Q; Li ZP; He B; Xu F; Shen YL; Gou HF; Yang Y; Cao D; Yi C; Liu JY; Luo DY; Liao ZY; Bi F
    Med Oncol; 2011 Dec; 28 Suppl 1():S274-9. PubMed ID: 21116880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection.
    Zhu WG; Xua DF; Pu J; Zong CD; Li T; Tao GZ; Ji FZ; Zhou XL; Han JH; Wang CS; Yu CH; Yi JG; Su XL; Ding JX
    Radiother Oncol; 2012 Sep; 104(3):361-6. PubMed ID: 22985776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
    Boda-Heggemann J; Hofheinz RD; Weiss C; Mennemeyer P; Mai SK; Hermes P; Wertz H; Post S; Massner B; Hieber U; Hochhaus A; Wenz F; Lohr F
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1187-95. PubMed ID: 19409725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
    Qiu M; Peng XC; Bi F; Wang X; Li Q; Xu F; Li ZP; Shen YL; Liu JY; Zhao YQ; Cao D; Gou HF; Yang Y; Chen Y; Yi C
    Med Oncol; 2015 Jul; 32(7):191. PubMed ID: 26025485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
    Quero L; Bouchbika Z; Kouto H; Baruch-Hennequin V; Gornet JM; Munoz N; Cojean-Zelek I; Houdart R; Panis Y; Valleur P; Aparicio T; Maylin C; Hennequin C
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):574-80. PubMed ID: 22099038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
    BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution.
    Bruixola G; Segura Á; Díaz-Beveridge R; Caballero J; Bennis MH; Palomar L; Giménez A; Mingol F; García-Mora C; Aparicio J
    Tumori; 2015; 101(5):517-23. PubMed ID: 26045120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.
    Minn AY; Hsu A; La T; Kunz P; Fisher GA; Ford JM; Norton JA; Visser B; Goodman KA; Koong AC; Chang DT
    Cancer; 2010 Aug; 116(16):3943-52. PubMed ID: 20564136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
    Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
    Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
    Kilic L; Ordu C; Ekenel M; Yildiz I; Keskin S; Sen F; Gural Z; Asoglu O; Kizir A; Aykan F
    Med Oncol; 2013; 30(3):660. PubMed ID: 23877872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection.
    Kim TH; Park SR; Ryu KW; Kim YW; Bae JM; Lee JH; Choi IJ; Kim YJ; Kim DY
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):e585-92. PubMed ID: 22975616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
    Wang X; Zhao DB; Yang L; Chi Y; Tang Y; Li N; Wang SL; Song YW; Liu YP; Liu WY; Ren H; Zhang T; Wang JY; Chen XS; Fang H; Wang WH; Li YX; Jin J
    Br J Cancer; 2018 Feb; 118(3):338-343. PubMed ID: 29235569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study.
    Badakhshi H; Gruen A; Graf R; Boehmer D; Budach V
    Gastric Cancer; 2014; 17(3):537-41. PubMed ID: 24122094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
    Chakravarty T; Crane CH; Ajani JA; Mansfield PF; Briere TM; Beddar AS; Mok H; Reed VK; Krishnan S; Delclos ME; Das P
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):581-6. PubMed ID: 22137021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach to delineating lymph node target volumes for post-operative radiotherapy in gastric cancer: A phase II trial.
    Haijun Y; Qiuji W; Zhenming F; Yong H; Zhengkai L; Conghua X; Yunfeng Z; Yahua Z
    Radiother Oncol; 2015 Aug; 116(2):245-51. PubMed ID: 26228969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.